NCT06455891|Completed
MYCobiome Analysis in Atopic Dermatitis With Head and Neck Involvement
MYCAH
Loading search results
MYCAH
Sponsor study identifier
Secondary identifiers
OTHER · IDRCB ANSM
observational
30
1 country
1
Study Start
May 14, 2024
Actual (reported)Primary Completion
December 17, 2025
Actual (reported)Study Completion
December 17, 2025
Actual (reported)It is an open study, explorative, proof of concept study concerning mycobiota dysbiosis implication in AD patients with head and neck involvement.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 17, 2025
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 7, 2024
Actual (reported)May 14, 2024
Actual (reported)June 12, 2024
Actual (reported)December 17, 2025
Actual (reported)December 17, 2025
Actual (reported)Description and comparison of head and neck mycobiome in AD patients, with generalized AD and HNAD, compared to head and neck mycobiome in controls.
To conduct a mycobiome analysis in the Head and Neck areas in adults with AD compared to healthy control using matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF) after culture. An additional analysis of the mycobiome by next generation sequencing (NGS) will also be carried out.
18 months
Lectins and gene polymorphism implicated in innate response to mycobiome in AD patients with head and neck involvement. 15 mL of blood will be collected.
18 months
Antifungal systemic immune response.
18 months
Patients with generalized AD defined by AD skin lesion involved more or equal 50% of total body surface area with head and neck involvement. (15 patients)
Patients with head and neck AD (HNAD) defined by AD involving at least 80% of the head and neck area with or without AD involvement outside the head and neck area but \<20% of total body surface area. (15 patients)
Healthy control without chronic skin disease. Healthy control will be recruited from non-atopic patients explored in ours departments for drug allergy after resolution of acute events. (15 healthy controls)
Adult, age between 18 and 65 years with generalized and head and neck AD treated with topical steroids and/or topical tacrolimus for AD.
Tenon Hospital APHP dermatology and allergology department
Paris, 75020, France
Morgan XC, Huttenhower C. Chapter 12: Human microbiome analysis. PLoS Comput Biol. 2012;8(12):e1002808. doi: 10.1371/journal.pcbi.1002808. Epub 2012 Dec 27.
Angèle SORIA, PU-PH
Assistance Publique - Hôpitaux de Paris
30 participants (actual enrollment reported by the registry).
First Submitted
May 7, 2024
First Posted
June 12, 2024
Study Start
May 14, 2024
Actual (reported)Evaluation of the Efficacy of a Cosmetic Care in Subjects With Moderate to Severe Atopic Dermatitis, Treated by Systemic Treatments
Contact the study team to confirm eligibility.
Primary Completion
December 17, 2025
Actual (reported)Study Completion
December 17, 2025
Actual (reported)Last Updated
March 11, 2026
Record last verified: 2026-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: